文献速递睡眠呼吸障碍

靶向联合药物治疗阻塞性睡眠呼吸暂停的前景与挑战

Can targeted combination pharmacotherapy find its mark in the treatment of obstructive sleep apnoea?
RSS 订阅 · Thorax

本文讨论阻塞性睡眠呼吸暂停(OSA)的药物治疗进展:PAP 虽有效但耐受性和依从性有限,非 PAP 治疗对部分患者有效但残留疾病常见。Tirzepatide 成为首个获 FDA 批准用于肥胖成人中重度 OSA 的药物,提示与直接针对上气道的靶向联合治疗不同的治疗范式。

要点

  • Tirzepatide 是首个获 FDA 批准用于肥胖成人中重度 OSA 的药物。
  • OSA 治疗需兼顾解剖与非解剖机制,如上气道肌肉反应性和通气稳定性。
  • PAP 有效但依从性有限,非 PAP 治疗常残留疾病。

核心结论

  • 药物联合靶向治疗 OSA 具有吸引力,但需区别于以 Tirzepatide 为代表的抗肥胖药物治疗范式。

研究设计与样本

  • 本文为 Thorax 期刊的评论性文章,未报告具体研究设计与样本量。

主要发现

  • Tirzepatide 成为首个获 FDA 批准用于肥胖成人中重度 OSA 的药物。
  • 非 PAP 治疗包括下颌前移装置、上气道手术和舌下神经刺激,对部分患者有效但残留疾病常见。
  • OSA 除解剖因素外还涉及上气道肌肉反应性受损、通气不稳定和觉醒阈值改变等非解剖特征。

临床怎么用

  • 对肥胖合并中重度 OSA 的成人,可考虑 Tirzepatide 药物治疗。
  • 临床选择 OSA 治疗时应关注患者对 PAP 的耐受性和残留疾病情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The search for an effective drug therapy for obstructive sleep apnoea (OSA) has long been driven by a familiar clinical reality: although positive airway pressure (PAP) remains highly efficacious, many patients do not tolerate it or do not persist with treatment. Alternative non-PAP options—including mandibular advancement devices, upper airway surgery and hypoglossal nerve stimulation—benefit selected patients but residual disease is common and treatment selection remains imperfect. 1 In this context, pharmacotherapy has particular appeal, especially for patients in whom OSA is driven not only by anatomical compromise but also by non-anatomical traits such as impaired upper-airway muscle responsiveness, ventilatory instability or altered arousal threshold. 2 The treatment landscape has recently shifted with the antiobesity drug, Tirzepatide, becoming the first FDA-approved medication for moderate-to-severe OSA in adults with obesity. 3 Importantly, this highlights a complementary but distinct therapeutic paradigm from endotype-targeted combination therapy aimed directly at upper-airway...

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Thorax:Can targeted combination pharmacotherapy find its mark in the treatment of obstructive sleep apnoea?

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。